OQS
UBX

Occudo Quantitative Strategies’s Unity Biotechnology UBX Stock Holding History

Occudo Quantitative Strategies’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-5,147
Closed -$58K – 1388
2022
Q1 		$58K Hold
5,147
– – ﹤0.01% 1069
2021
Q4 		$75K Sell
5,147
-80
-2% -$1.75K 0.01% 986
2021
Q3 		$157K Sell
5,227
-1,252
-19% -$44.2K 0.02% 890
2021
Q2 		$301K Buy
+6,479
New +$312K 0.05% 594

Other funds holding UBX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FFVM
Founders Fund V Management San Francisco, California $2.16M AUM 77.37% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Occudo Quantitative Strategies's UBX Position: Q2 2022 in Review

Occudo Quantitative Strategies sold out of Unity Biotechnology (UBX) in Q2 2022, closing a stake of 5,147 shares — an estimated $58K sold.

Occudo Quantitative Strategies first reported a position in UBX in Q2 2021 and held it in 4 quarters. The position peaked at $301K in Q2 2021. 65 funds tracked by Wall St. Rank hold UBX as of Q2 2022.

  • Occudo Quantitative Strategies reported no remaining Unity Biotechnology position as of Q2 2022 after selling out during the quarter.
  • Occudo Quantitative Strategies sold 5,147 Unity Biotechnology shares in Q2 2022, an estimated $58K.
  • Occudo Quantitative Strategies first reported a position in Unity Biotechnology in Q2 2021 and held it in 4 quarters.
  • Occudo Quantitative Strategies's Unity Biotechnology position peaked at $301K in Q2 2021.
  • 65 funds tracked by Wall St. Rank held Unity Biotechnology as of Q2 2022.

Based on Occudo Quantitative Strategies's 13F filing for Q2 2022, filed 15 Aug 2022.